1 / 4

MENINGOCOCCAL POLYSACCHARIDE

MENINGOCOCCAL POLYSACCHARIDE. For those at risk. 10-65 yo without evidence of immunity. Allergy to a prior dose, allergy to gelatin /neomycin, pregnancy, those on large doses of steroids. Allergy to one component, defer if with moderate-severe illness. PNEUMOCOCCAL POLYSACCHARIDE.

hei
Download Presentation

MENINGOCOCCAL POLYSACCHARIDE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MENINGOCOCCAL POLYSACCHARIDE For those at risk 10-65 yo without evidence of immunity Allergy to a prior dose, allergy to gelatin/neomycin, pregnancy, those on large doses of steroids Allergy to one component, defer if with moderate-severe illness PNEUMOCOCCAL POLYSACCHARIDE Single dose, revaccinate after 5yrs Adolescents/adults: 2 doses (0,1 mos) Anyone starting at 6mos For all susceptible esp. >50yo, for those without previous vaccine, give PCV13 followed by PPSV23 after 8wks;if 2nd dose of PPSV23 is required, give 5 yrs after Allergy to phenol/thimerosal, moderate-severe illness +/- fever Anaphylaxis with a prior dose, moderate-severe illness +/- fever, age<6mos, active GuillanBarre syndrome, egg allergy Single IM dose 1x/yr (Feb-June) Pregnancy/lactation not contraindication Single dose, revaccinate after 5 yrs for high risk patient Contraindicated Given if needed Given at any trimester 1dose during each pregnancy at 27-36wks HPV4 (0,2,6 or 0,1,4) HPV2 (0,1,6) 3 doses: 0,1,6-12mos Booster every 10yrs If found to be pregnant, remaining doses given after delivery Severe allergy to a prior dose Moderate-severe illness +/-fever’ allergy to thimerosal, allergy to prior dose, bleeding disorders TETANUS, DIPHTHERIA, PERTUSSIS HPV4 & HPV2 routinely given to females 9-19yo; catch up vaccination: 19-45yo for HPV4, 19-55yo for HPV2, HPV4 also given to males 9-26yo Td every 10yrs; TDaP recommended as one-time substitute dose for persons aged 10-64yo HUMAN PAPILLOMA VIRUS Contraindicated Pregnancy/lactation not contraindicated 2 doses (0,1 mos) 3doses (0,1,6);accelerated 4 doses (0,7,21days,12 mos) Given if needed Pregnancy, allergy to prior dose, malignant conditions of bone marrow/lymphatic system, 1°/acquired immunodeficiency, on high dose immunosuppressants/low dose steroids >2wks 2doses (0,6-12mos) Allergy to a vaccine component, not given to those highly febrile Allergy to a vaccine component, not given to those highly febrile Universal immunization of all infants, adolescents, adults Recommended for all adults/adolescents with no evidence of immunity VARICELLA HEPATITIS B For all living in areas of high prevalence (eg. Asia) HEPATITIS A

  2. Indications Contraindications Dose Pregnancy Perforated hole Injectable Vaccine Administration Guidelines for Adolescents & Adults Vaccine Storage Route Site Hepatitis A R IM Deltoid Hepatitis B R IM Deltoid HPV R IM Deltoid Influenza R IM Deltoid MMR R* SC Lateral upper arm Meningococcal R IM Deltoid Pneumococcal R SC Lateral upper arm IM Deltoid Td/TDaP RIM Deltoid Varicella R SC Lateral upper arm *can freeze lyophlized MMR powder but not diluent R-refrigerator F-freeze IM-intramuscular SC-subcutaneous 2013 POGS IFW RECOMMENDATIONS

  3. MENINGOCOCCAL POLYSACCHARIDE Persons born in or after 1957 without prior proof of immunity or documentation of one or more dose; persons with recent exposure to measles or mumps or in an outbreak setting; persons who were previously vaccinated with killed measles vaccine; persons who were vaccinated between 1963-1967; college students; those in postsecondary education institutions; health care workers; international travellers; women who lack laboratory evidence of immunity Previously unvaccinated adolescents (prior to high school entry); students in dormitories; microbiologists; military recruits; persons travelling to or living in hyperendemic/endemic areas; asplenia; complement component deficiencies PNEUMOCOCCAL POLYSACCHARIDE Persons > 50 y/o; persons with chronic illnesses; asplenia; immunocompromised patients; persons receiving chemotherapy, antimetabolites, high dose long term corticosteroids; residents of long term care facilities Persons with chronic illnesses; women who will be pregnant during the influenza season; health care workers; residents of nursing homes or long term care facilities; persons likely to transmit influenza to persons at high risk Td: adults including pregnant women with uncertain histories of a complete primary vaccination series or whose last vaccination was 10 years or more Tdap: 10-64 y/o, pregnant women who have not received Tdap; health care workers and those in a high risk pertussis environment TETANUS, DIPHTHERIA, PERTUSSIS Persons who are or will be sexually active HUMAN PAPILLOMA VIRUS Persons with >1 sex partner in the past 6 months; STI clinic clients; household contacts and sexual partners of individuals with chronic Hepatitis B infection; men who have sex with men; injection-drug users; persons in institutions for the disabled; health care workers; HIV infection; travellers to endemic areas; inmates of correctional facilities Persons who do not have a reliable history of varicella infection, previous vaccination, or serological evidence of prior varicella zoster virus infection; adolescents and adults who previously received only one dose Persons with clotting disorders or chronic liver disease; men who have sex with men; illegal drug users; persons with occupational risk; persons travelling to or working in endemic areas VARICELLA HEPATITIS B HEPATITIS A

  4. WHO IS AT RISK? General Principles of Vaccination: • Vaccination is ideally universal in coverage. • Vaccination is a primary healthcare service. • Can be given by any at all healthcare encounters. General Considerations for Vaccination: • Never administer vaccines in buttock • Maintain vaccine administration record in patient’s chart including date, site, and route of administration; manufacturer and lot number of vaccine • Simultaneous administration of vaccines is not contraindicated. • The presence of a pregnant woman or immunosuppressed person in the household is not a reason to withhold an indicated vaccine to a family member . • If a live attenuated vaccine is not given simultaneously with another vaccine, a 4-wk interval should be used between vaccinations. IMMUNIZATIONS

More Related